Findings from a clinical trial led by Rockefeller University scientists as reported by journal Nature highlight anti-HIV antibodies as a novel treatment option; one that wouldn’t rely on vigilant daily dosing and could potentially reduce the body’s reservoir of HIV, which conventional antiretroviral drugs cannot do. Read the full article here […]
RIO Trial protocol published in the journal Trials
5 April 2022, 23, Article number: 263 We are pleased to report that the RIO Trial protocol has now been published in the peer-reviewed journal Trials. Please find the full manuscript here. […]
RIO trial update
We are delighted to note that we are currently recruiting in all 7 clinical sites across London and Brighton and will shortly be opening 3 new sites at St George’s Hospital in London, Western General Hospital in Edinburgh and North Manchester General Hospital. To date we have recruited and dosed 20 participants into the study. […]
BBC News: “Rare case of woman’s body ridding itself of HIV”
RIO Chief Investigator Prof Sarah Fidler and Protocol Co-Chair Prof John Frater interviewed. 17 November 2021 A woman from Argentina appears to have rid herself of HIV without drugs or treatment – the second documented case of its kind in the world. Doctors believe the patient’s immune system cleared the virus on its own. Tests […]
RIO Patient Representative, Mr Simon Collins, wins biennial EACS Award
Simon Collins was the joint award winner at the 18th European AIDS Conference held on the 27th – 30th October 2021. “The [opening] ceremony ended with the presentation of the biennial EACS Award in recognition of an individual’s longstanding, impactful and sustained professional contribution to the field of HIV. In 2021 a joint award was […]
RIO trial represented at EACS 2021
The 18th European AIDS Conference (EACS) took place on the 27th – 30th of October 2021 both in London and online. From the RIO study team, Professors Sarah Fidler, Marina Caskey and John Frater and our Patient Representative Mr Simon Collins were part of the scientific programme of the conference. Prof Fidler chaired a session […]
RIO trial opens for recruitment
The RIO clinical trial will test whether a new type of therapy can keep HIV under control without daily antiretroviral treatment (ART) tablets. The novel therapy uses a combination of two experimental antibodies (called broadly neutralising monoclonal antibodies, or bNAbs) which have been designed by scientists at the Rockefeller University to target multiple strains of […]
RIO trial protocol preprint available on Research Square
Read about our #RIOtrial protocol, and the benefits of early and integrated community involvement during study design. […]
